Search

everythinglearnresearchcommunity

for

Search:↓

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.

Baricitinib improved hair loss and arthritis in a lupus patient.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.

Platelet-rich plasma may help restore immune balance in bald patches, but its effectiveness in treating hair loss is limited.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

Hepatitis C treatment may cause frontal fibrosing alopecia.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

2-deoxy D-glucose does not help with hair regrowth in alopecia areata.

5α-reduced progestogens may reduce mood issues and brain damage linked to HIV-1 Tat.

Steroid injections are more effective than platelet rich plasma for treating patchy hair loss.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.